A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets

Launched by ABBVIE · Jan 19, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a medication called Venetoclax is for treating adults with acute myeloid leukemia (AML), a type of blood cancer. This study is specifically for people who are newly diagnosed with AML and cannot undergo intensive chemotherapy, which is a common treatment for this disease. Approximately 120 participants will be involved, and they will take Venetoclax tablets daily for about two years. The trial is taking place at various sites in Switzerland and Austria.

To be eligible for this study, participants need to have a recent diagnosis of AML and should be able to receive Venetoclax as determined by their doctor. It’s important to note that doctors will decide to start Venetoclax treatment before discussing the study with patients. Participants can expect routine follow-up visits during their treatment, and there will be no extra burden from being part of this trial, as visits will align with their regular medical care. This study is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly-diagnosed AML and eligible to receive venetoclax as per local label.
• • Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.
• Exclusion Criteria:
• • - Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.